| 摘要 |
This application relates to a compound of Formula I (see formula I) or a pharmaceutically acceptable salt thereof, as defined herein, pharmaceutical compositions thereof, and its use as an antagonist of receptor CRTH2, as well as a process for its preparation and intermediates therefor. |
